On June 3, Santen Pharmaceutical Co., Ltd. (Santen Pharmaceutical Co., Ltd.) announced the appointment of ShawnXiang (ShawnXiang) as the new executive director (executive) and president of the Chinese region to lead the Chinese market business, including business strategy and sales promotion, product portfolio management, and business practices in the Chinese market. The appointment is effective as of June 3, 2024. Prior to joining Santian, Xiang Yu served as CEO of RareStoneGroup (RareStoneGroup).
参天公司任命向宇为中国区总裁
Santen appoints Xiang Yu as president of China
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.